The journal Andrology has published a multicentric study on RISUG (Reversible Inhibition of Sperm Under Guidance) conducted by ICMR at five sites across India.

It is a prospective, non-randomized, open-labeled, phase III clinical trial.

It studied the effect of RISUG by injecting 60mg of Styrene Maleic Anhydride (SMA) in a vehicle of Di-Methyl Sulphoxide (DMSO) in the vas deferens of 303 healthy, sexually active, married males (age group- 25-40 years) attending family planning clinics.

The study reported that azoospermia observed in various centers ranged from 76.5% to 96.5%, with two centers reporting 100% azoospermia.

The trend remained the same until the seven-year follow-up.